Orthofix M6-C Artificial Cervical Disc IDE Study Data to be Presented at ISASS Demonstrates Continued Statistically Significant Benefits at Five Years – Yahoo Finance

Additionally, analysis of two-year physiological range of motion data from multiple artificial cervical disc IDE studies to be presented showing benefits of the nucleus-annulus design of the M6-C disc
LEWISVILLE, Texas, May 31, 2022–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of five-year data from the M6-C artificial cervical disc single-level IDE study. These results will be presented on Friday, June 3 during the International Society for the Advancement of Spine Surgery (ISASS) annual meeting at The Atlantis Hotel in Nassau, Bahamas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531005173/en/
Clinical data infographic for the M6-C artificial cervical disc. (Graphic: Business Wire)
“We are pleased to see that at five years postoperative, participants in the study who received the M6-C artificial cervical disc continue to show significant benefits in Neck Disability Index (NDI) scores and neck and shoulder/arm pain Visual Analog Scale (VAS) scores compared to patients who received anterior cervical discectomy and fusion (ACDF),” said Dr. Frank Phillips, Professor of Orthopedic Surgery at Rush University Medical Center and an investigator in the study, who will present the data at the ISASS meeting. “Additionally, M6-C patients in the study had a low rate of revision surgery compared to the ACDF cohort. Patients in the study will be monitored out to 10 years post-op as we continue to compile the data supporting the efficacy and benefits of cervical disc arthroplasty with the M6-C disc.”
U.S. IDE study results at five years indicate:
At five years, patients receiving the M6-C disc experienced a mean NDI improvement from the baseline of 47.5 points compared to 33.4 for the ACDF cohort, significantly better for the M6-C disc group.
Statistically significant favorable results were observed in shoulder/arm pain VAS scores at five-years, with a mean of 0.5 for M6-C disc study patients and 2.1 for ACDF participants. There was a mean improvement from baseline of 6.8 for M6-C disc patients compared to 5.2 for the ACDF cohort.
At the five-year endpoint, the M6-C artificial cervical disc continues to demonstrate one of the lowest Subsequent Surgical Interventions (SSI) rates at 3.1 percent when compared to other FDA-approved artificial cervical discs, suggesting that these rates are consistent with data reported for other FDA approved devices.
Through five years post-op, five M6-C study patients experienced SSIs at the index level. Of the removals, two were performed due to persistent neck and arm pain (with one being replaced by a new M6-C disc,) and one was performed due to bone loss associated with a confirmed infection. In the ACDF cohort, 11 patients underwent SSIs during the five-year post-op period.
In addition to Dr. Phillips’s presentation of the five-year IDE trial data, Dr. Avinash Patwardhan, Director of the Musculoskeletal Biomechanics Laboratory at Edward Hines Jr. VA Hospital will present analysis of data regarding the likelihood of achieving physiological range of motion after cervical disc arthroplasty on Friday, June 3, during the annual meeting. This research aimed to calculate the proportion of reconstructed disc segments which yielded flexion-extension motion in the physiological range (defined as 5-16 degrees) by analyzing 24-month postoperative data reported from clinical trials of various cervical disc prostheses. On average, two-thirds of implanted segments in this cohort achieved two-year post-cervical disc arthroplasty in the 5–16-degree range, meeting the functional goals of mobility and stability after Cervical Disc Arthroplasty (CDA).
“Mobility and stability are two essential requirements which allow a spinal segment to function in harmony with its neighboring segments,” said Dr. Avinash Patwardhan. “The M6-C disc, with its inherent progressive resistance to motion provided by the nucleus-annulus design, yielded the highest proportion (103/131 or 79 percent) of implanted segments in the physiological motion range compared to the cohort average of 65 percent. These results support the functional goals of CDA which include restoring segmental range of motion and reducing the risk of accelerated adjacent segment degeneration.”
“We continue to be pleased with the U.S. IDE clinical data that now includes five-year outcomes,” said Orthofix President of Global Spine Kevin Kenny. “We recognize the importance of the ongoing collection of data from the U.S. study and implanting centers around the globe in order to expand the body of evidence that supports the clinical performance and safety of the M6-C artificial cervical disc. We look forward to continuing to disseminate and publish that data.”
About the M6-C Artificial Cervical Disc
The M6-C artificial cervical disc was commercialized outside of the United States in 2006 and has an established robust clinical history with over 60,000 discs implanted in over 20 countries, with more than 12,000 having been implanted for more than 10 years, and 25,000 implanted for more than 7 years. In addition, more than 45,000 M6-C devices were implanted prior to U.S. FDA approval.
To learn more, please visit us at booth #400 at the ISASS annual meeting.
About Orthofix
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The Company’s mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries via the Company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2020 Form 10-K”). In addition to the risks described there, factors that could cause or contribute to such differences may include, but are not limited to: the risk that FDA approvals may be delayed or not be obtained; the risk that surgeons may be slow to adopt the M6-C artificial cervical disc; the risk that future patient studies or clinical experience and data may indicate that treatment with the M6-C artificial cervical disc does not improve patient outcomes as much as previously believed, or otherwise call into question the benefits of its use to patients, hospitals and surgeons; the risk that the product may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may decline to reimburse healthcare providers for the use of our products.
This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005173/en/
Alexa Huerta
Investor Relations
Tel 214 937 3190
[email protected]
Denise Landry
Media Relations
Tel 214 937 2529
[email protected]
Related Quotes
Dr. Shankar Musunuri, the CEO and co-founder of Ocugen, said the company's next step will be working with the FDA to create a Phase 3 testing program.
Did markets hit a turning point? The past couple of months brought us a seven-week losing streak in stocks, the longest such streak in over a decade, but the week before the Memorial Day holiday weekend saw strong gains. The S&P 500 wiped out its May losses. Post-holiday trading shows that some of these gains are continuing. If so, then it makes this the ideal time to ‘buy the dip,’ to get in while stocks remain at low cost, with attractive entry points. That’s the view from investment firm JPMo
Sage stock popped Wednesday after its Biogen-partnered treatment for postpartum depression met every goal in a final-phase study.
"For many Disabled people, food delivery services are imperative for our well-being; it’s not a luxury, but something we’re dependent on."View Entire Post ›
Millions of people live in rural communities, including close to one-quarter of seniors who may not have access to reliable transportation. Homeward is bringing healthcare directly to them at home and where they shop.
Biogen and Sage Therapeutics said new data allows them to seek approval for their depression medication zuranolone as a treatment for postpartum depression early next year.
A Brazilian sequencing program for EB patients brings access to more accurate diagnoses and better treatment
Many gyms and health clubs seem to be filling up again with people eager to return to their old routines and communities or get in shape for summer — at the same time that new omicron variants are pushing COVID infections up. So how safe is it to go back to the gym? Put another way, how many microscopic aerosol particles are the other cyclists in your spin class breathing out into the room? How many is the runner on the nearby treadmill spewing forth? A small study about respiration and exercise
The most recent variants of COVID-19 have seemingly evolved to be milder, especially if you're vaccinated and boosted. But one factor hasn't changed: Contracting COVID puts you at risk of developing long-lasting symptoms, a.k.a. long COVID, and a study released this week indicate that vaccines aren't much protection. Dr. Anthony Fauci, the nation's top infectious-disease expert, has warned about some of these potential symptoms. Read on to find out more—and to ensure your health and the health o
We're now two years into the pandemic, and people all across the U.S. are still getting infected with the coronavirus. According to the latest data from the Centers for Disease Control and Prevention (CDC), there have been more than 83 million total cases throughout this time, with a daily average of nearly 110,000 infections happening across the country right now. At this point, most of us likely feel like we know all there is to know about how we can catch COVID and what to do to protect ourse
The Bachelorette alum removed her breast implants in July 2021 after experiencing numerous health concerns over the years
Thee Jane's Addiction guitarist says he's "been sick since December."
Young women are more concerned about the mental health impact of being online than other internet users, with many citing personal safety fears and the harm caused by trolling, a study by Britain's media watchdog has found. Regulators and activists across the world are increasingly calling on Big Tech companies to tackle hate speech on online platforms, a plea echoed by the head of Britain's Ofcom regulator as she unveiled the report on internet usage. "The message from women who go online is loud and clear," Ofcom Chief Executive Melanie Dawes said in a statement on Wednesday.
Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded the availability of SPRAVATO® to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. Starting June 1, the KWC clinics in Minneapolis, Salt Lake City and Dallas will join the Houston, Las Vegas and Seattle locations in offering SPRAVAT
James MacDougall fathered 15 children without telling the women using his services that he had fragile-X syndrome.
The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.
The philosopher kings will rule until we have a constitutional amendment that defines the limits of judicial supremacy.
1. What are nasal vaccines? Nasal vaccines are administered, as the name suggests, through the nose. More accurately called intranasal vaccines, these vaccines are liquids that can be given as a spray or through a dropper or syringe.
Eating a well-balanced, nutritionally packed diet is one of the best things you can do for your physical health. Experts say your cognitive health can also get a boost from getting the right vitamins and minerals—and alhough no one vitamin or supplement can prevent the development of dementia, deficiencies of certain vitamins have been linked with an increased risk of dementia. Read on to learn which four vitamins are considered crucial to your cognitive health, and which foods can help you get
When it comes to long COVID, there are clearly “different pathologies at play,” one expert told Fortune.